Old Web
English
Sign In
Acemap
>
authorDetail
>
Michael Montemurro
Michael Montemurro
University of Zurich
Sorafenib
Nilotinib
Protein kinase inhibitor
Imatinib
Tyrosine kinase
2
Papers
22
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Sorafenib with or without everolimus in patients with unresectable hepatocellular carcinoma (HCC): A randomized multicenter phase II trial (SAKK 77/08 and SASL 29).
2014
Journal of Clinical Oncology
Dieter Koeberle
Jean-François Dufour
Gyula Demeter
Panagiotis Samaras
Piercarlo Saletti
Qiyu Li
Arnaud Roth
D. Horber
Michael Buehlmann
Anna-Dorothea Wagner
Michael Montemurro
Gábor Lakatos
Karin Ribi
Jonas Feilchenfeld
Markus Peck-Radosavljevic
Daniel Rauch
Ivana Cvijetic
Britta Tschanz
Gyorgy Bodoky
Show All
Source
Cite
Save
Citations (2)
Important role of CYP2J2 in protein kinase inhibitor degradation: a possible role in intratumor drug disposition and resistance.
2014
PLOS ONE
Céline Narjoz
Amélie Favre
Justin McMullen
Philippe Kiehl
Michael Montemurro
William D. Figg
Philippe Beaune
Isabelle de Waziers
Bertrand Rochat
Show All
Source
Cite
Save
Citations (20)
1